Miami, FL (April 28, 2021) – Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced positive results for the first ten COVID-19 patients treated with Zofin™ in India. This initial trial is being conducted in conjunction with Organicell’s Indian partner, CWI India, with whom Organicell entered into a product testing and distribution agreement on February 9, 2021 to study the effects of Zofin™ on moderate to severe COVID-19 patients. [Read more…]
Stem Cell News
BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.
As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.
Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.
Breakthrough Paper Outlines Path to Heart Regeneration After Cardiac Injury
A groundbreaking study from Neobiosis, a global expert in regenerative medicine, explains how a never-before-described process may open the door to regenerating damaged hearts. A peer-reviewed research paper from Dr. Ian White published in the journal Stem Cells and Regenerative Medicine explains how his studies of mouse hearts could be used to defeat a disease that kills 650,000 Americans each year.
ALACHUA, FLA., APRIL 21, 2021 – Cardiovascular disease kills more than 650,000 Americans annually.(1) Those who survive myocardial infarction remain at risk of death because the human heart has a very limited ability to repair itself. No one has yet found a method that leads to cardiovascular regeneration for a damaged human heart. But all that may change thanks to a revolutionary medical paper written by Dr. Ian White, President and CSO of Neobiosis, a company that focuses on the science of regenerative medicine.
Organicell Completes Enrollment For Its Expanded Access Trial To Treat COVID-19 Patients With Zofin™
Miami, FL (April 22, 2021) — Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that the company has completed enrollment for its U.S. Food and Drug Administration (FDA) granted expanded access trial for Zofin for the treatment of COVID-19. [Read more…]
Organicell Announces FDA Approval Of IND Application For The Use Of Zofin™ In The Treatment Of Osteoarthritis
Miami, FL (April 21, 2021) — Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its lead product, Zofin™, in the treatment of knee osteoarthritis. [Read more…]
APEX Biologix Expands its Footprint Through Investment by Desert Highlands Regenerative
Merger enables an increased focus on product innovation, more cutting-edge regenerative medicine research and strategic collaborations with other complementary technology companies.
Salt Lake City, UT (April 16, 2021) – Desert Highlands Regenerative (DHR), a private equity group, has acquired a majority ownership of APEX Biologix (APEX), the designers and manufacturers of the XCELL Platelet Rich Plasma (PRP) and other regenerative medicine products. APEX also appointed to its senior management team Jeff Frey as Chief Commercial Officer. Jeff’s orthopedic and regenerative medicine experience spans 25 years with companies such as Johnson & Johnson Orthopedics, Integra Lifesciences, and Ortho Solutions. [Read more…]
- « Previous Page
- 1
- …
- 51
- 52
- 53
- 54
- 55
- …
- 123
- Next Page »